The ratio of cardiac troponin T to troponin I may indicate non-necrotic troponin release among COVID-19 patients.

Hammarsten O, Ljungqvist P, Redfors B, Wernbom M, Widing H, Lindahl B, Salahuddin S, Sammantar R, Jha S, Ravn-Fisher A, Brink M, Gisslen M

Clin Chim Acta - (-) - [2022-01-05; online 2022-01-05]

Although cardiac troponin T (cTnT) and troponin I(cTnI) are expressed to similar amount in cardiac tissue, cTnI often reach ten-times higher peak levels compared to cTnT in patients with myocardial necrosis such as in acute myocardial infarction (MI). In contrast, similar levels of cTnT and cTnI are observed in other situations such as stable atrial fibrillation and after strenuous exercise. Examine cTnT and cTnI levels in relation to COVID-19 disease and MI. Clinical and laboratory data from the local hospital from an observational cohort study of 27 patients admitted with COVID-19 and 15 patients with myocardial infarction (MI) that were analyzed with paired cTnT and cTnI measurement during hospital care. Levels of cTnI were lower than cTnT in COVID-19 patients (TnI/TnT ratio 0.3, IQR: 0.1-0.6). In contrast, levels of cTnI were 11 times higher compared to cTnT in 15 patients with MI (TnI/TnT ratio 11, IQR: 7-14). The peak cTnI/cTnT ratio among the patients with MI following successful percutaneous intervention were 14 (TnI/TnT ratio 14, IQR: 12-23). The 5 COVID-19 patient samples collected under possible necrotic events had a cTnI/cTnT ratio of 5,5 (IQR: 1,9-8,3). In patients with COVID-19, cTnT is often elevated to higher levels than cTnI in sharp contrast to patients with MI, indicating that the release of cardiac troponin has a different cause in COVID-19 patients.

Category: Biochemistry

Category: Health

Funder: Hjärt-Lungfonden

Funder: KAW/SciLifeLab

Funder: VR

Research Area: Biobanks for COVID-19 research

Type: Journal article

PubMed 34998858

DOI 10.1016/j.cca.2021.12.030

Crossref 10.1016/j.cca.2021.12.030

pii: S0009-8981(21)00459-9

Publications 7.0.1